Auris Medical (EARS) Releases Quarterly Earnings Results

Auris Medical (NASDAQ:EARS) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01), MarketWatch Earnings reports.

Shares of NASDAQ:EARS traded down $0.01 on Friday, hitting $0.40. The company had a trading volume of 7,027 shares, compared to its average volume of 1,787,490. Auris Medical has a 1-year low of $0.23 and a 1-year high of $3.08. The company has a market cap of $15.19 million, a P/E ratio of -0.07 and a beta of -0.56.

Several research firms have commented on EARS. Zacks Investment Research upgraded shares of Auris Medical from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a report on Tuesday, January 1st. ValuEngine upgraded shares of Auris Medical from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Roth Capital began coverage on shares of Auris Medical in a report on Thursday, December 20th. They issued a “buy” rating and a $5.00 price objective on the stock.

COPYRIGHT VIOLATION NOTICE: “Auris Medical (EARS) Releases Quarterly Earnings Results” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://sportsperspectives.com/2019/03/15/auris-medical-ears-releases-quarterly-earnings-results.html.

About Auris Medical

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Further Reading: Bear Market – How and Why They Occur

Earnings History for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.